Latest Nura Bio News & Updates

See the latest news and media coverage for Nura Bio. We track all announcements, press releases, and industry mentions in real time, all in one place.

Company icon
Nura Bio

Neuroprotective therapies developer

nurabio.com
Headquarters
South San Francisco, United States
Founded year
2018
Company type
Private company
Number of employees
30–50

Latest news about Nura Bio

Company announcements

  • Nura Bio

    Nura Bio appoints C-suite executives

    Lahar Mehta, M.D. as Chief Medical Officer and Scott Greenberg as Chief Business Officer to advance clinical pipeline.

  • Nura Bio

    Nura Bio closes Series A financing with $68M

    Total raised exceeds $140M. Appoints Shilpa Sambashivan as CEO. Completes Phase 1 of NB-4746.

  • Nura Bio

    Nura Bio initiates Phase 1 trial for NB-4746

    NB-4746 is an oral, brain-penetrant SARM1 inhibitor for neurological diseases like ALS and MS. This marks Nura Bio's transition to a clinical-stage company.

  • Nura Bio

    Nura Bio reports preclinical data on SARM1 inhibitors

    Data validates conserved NAD hydrolase inhibition mechanism for neurodegeneration neuroprotection. Publication in Neuron supports First-in-Human trials in early 2023.

Unlock all announcements with a

Media coverage

  • Yahoo Finance

    Nura Bio Expands Leadership Team with C-Suite Appointments

    Scott Greenberg, Chief Business Officer, Nura Bio Inc. (Photo: Business Wire) "At Nura Bio, we have made significant progress in developing our company and pipeline...

  • Healio

    Nura Bio announces phase 1 study for oral, brain-penetrant SARM1 inhibitor

    We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. A Bay Area-based biopharmaceutical...

  • BioWorld

    Nura Bio presents new SARM1 inhibitors for neurological disorders

    BioWorld - Monday, October 7, 2024 Breaking News: BioWorld celebrates nine wins at 2024 APEX Awards See today's BioWorld Science Home » Nura Bio presents...

  • Business Wire

    Nura Bio Reports Preclinical Data Validating a Conserved Mechanism of Inhibition of NAD Hydrolases Implicated in Neurodegeneration in Neuron

    SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Nura Bio Inc., a biopharma company based in South San Francisco, focused on the discovery and development of disease-modifying neuroprotective drugs...

Unlock all articles with a

Never miss news about Nura Bio

Track Nura Bio and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Nura Bio competitors & trending companies

Browse news for competitors to Nura Bio and other trending companies.